retatrutide ly3437943 parkinson's disease clinical trial of Lixisenatide in Early A Study of Retatrutide (LY3437943)

GLP-1 Receptor Agonists GLP-1 agonists and GLP-1/GIP dual agonists is the ability to target more than one metabolic pathway

The brain-penetrant GLP-1RA NLY01 significantly attenuated microglial activation and improved clinical outcomes in EAE models

What UK Health Authorities Say About NAD+ Supplements UK regulatory bodies have not issued specific guidance on NAD+ patches, but their oversight falls under existing frameworks for consumer products, medical devices, or medicines depending on their specific claims and mode of action

Diabetes Care

8.5 Geriatric Use SYMLIN has been studied in patients ranging in age from 15 to 84 years of age, including 769 patients 65 to 75 years of age and 87 patients 75 years of age

Exenatide reverts the high-Fat-Diet-Induced impairment of BDNF signaling and inflammatory response in an animal model of alzheimers disease